Here are four things to know:
1. The trial will run alongside the two ongoing pivotal U.S. Phase III trials in colonoscopy and bronchoscopy.
2. The trial is part of the development program that PAION and the FDA agreed upon for the filing of Remimazolam in the targeted indication ‘procedural sedation’.
3. Remimazolam is an ultra-short-acting intravenous sedative and anesthetic.
4. This double-blind, randomized, multicenter, parallel group study includes around 75 high-risk patients undergoing a colonoscopy.
More articles on GI/endoscopy:
ASGE launches clinical practice guideline app: 3 things to know
Dr. Noel Fajardo to open LV Surgery Center in Nevada: 3 things to know
Giving thanks in GI: 5 gastroenterologists on what they are most grateful for
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.